• Signed Informed Consent Form

• Age ≥ 18 years

• Able to comply with the study protocol in the investigator's judgment

• Clinically and radiologically (contrast CT, full profile MRI - T1-weighted with or without contrast, T2-weighted, FLAIR, DWI, PWI, MR-spectroscopy) confirmed diagnosis of GBM, localized outside eloquent brain areas

• Resectable tumor

• Fully physically active ≥80 points in Karnofsky performance scale

• Life expectancy of at least 3 months

• Adequate organ function (confirmed within 1 weeks before enrollment):

∙ Hemoglobin ≥ 9g/dL

‣ Absolute Neutrophils Count (ANC) ≥1.5×109/L

‣ White Blood Cells (WBC) count ≥3×109/L

‣ Platelets (PTL) ≥ 100×109/L

‣ AST/ALT ≤2.5×ULN

‣ Serum creatinine (S-Cr) ≤ ULN

‣ Glomerular Filtration Rate (GFR) ≥50mL/min

‣ Albumin ≥ LLN

‣ Bilirubin ≤ 1.5 ULN (except patients with documented Gilbert's Syndrome, who must present adequate level of direct bilirubin)

∙ International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN. (Elevation of INR and aPTT due to administration of anticoagulation drugs is not a contraindication for the enrollment. However, it must return to normal range prior to surgery).

⁃ For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use double barrier contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 120 days after the last immuno-PET imaging.

⁃ For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use double barrier contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 120 days after the last immuno-PET imaging.